This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens' (WBA) tie-ups with Alphabet's life sciences and healthcare segment, Verily on multiple projects related to chronic ailments buoy optimism.
Rite Aid Adds More Testing Sites in Fight Against Coronavirus
by Zacks Equity Research
Rite Aid (RAD) is aggressively expanding COVID-19 testing locations by adding 21 more sites in order to curb the effects of coronavirus.
Pharmacies & Drug Stores Outlook Dull Amid Coronavirus Crisis
by Urmimala Biswas
Amid the coronavirus-led worldwide sales disruption, the retail pharmacy and drug store industry is witnessing a bloodbath.
3 Cheap Stocks Under $10 to Buy Now for Coronavirus Reopening Rally
by Benjamin Rains
Today we look at three "cheap" stocks trading under $10 a share that might be worth buying as the market continues to march higher on coronavirus reopening optimism and more...
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $43.55, moving +0.58% from the previous trading session.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $42.97, marking a +1.92% move from the previous day.
Top Analyst Reports for Alibaba, Chevron & Shopify
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Chevron (CVX) and Shopify (SHOP).
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $40.14, moving +0.93% from the previous trading session.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $41.70 in the latest trading session, marking a +0.06% move from the prior day.
Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $42.02, marking a -1.01% move from the previous day.
The 5 Cheapest Dow Stocks Right Now
by Tracey Ryniec
Looking for bargains among the large cap stocks? Some of the Dow Jones stocks are cheaper than the average valuation of the S&P 500 and are paying dividends too.
Rite Aid (RAD) Expands Coronavirus Testing Site to Virginia
by Zacks Equity Research
Rite Aid (RAD) is aggressively expanding COVID-19 testing locations, marked by the opening of its 25th site at Richmond, VA, to help curb the effects of the pandemic.
Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis
by Zacks Equity Research
Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.
The Zacks Analyst Blog Highlights: Comcast, Bristol-Myers Squibb, Walgreens Boots Alliance, UnitedHealth and Xcel Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Bristol-Myers Squibb, Walgreens Boots Alliance, UnitedHealth and Xcel Energy
Rite Aid's (RAD) Q4 Loss Wider Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Strong revenues at pharmacy services and retail pharmacy segments aided Rite Aid's (RAD) Q4 results. Further, management issued FY21 view, which reflects no COVID-19 impacts.
Top Research Reports for Comcast, Bristol-Myers & Walgreens
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Bristol-Myers Squibb (BMY) and Walgreens Boots Alliance (WBA).
Company News for Apr 3, 2020
by Zacks Equity Research
Companies In The News Are: NEPT, BMRA, LK, WBA
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The coronavirus outbreak had an immaterial impact on Walgreens Boots' (WBA) second-quarter fiscal 2020 results.
Walgreens Boots Alliance (WBA) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 4.83% and 1.48%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Walgreens Boots Alliance (WBA) Might Surprise This Earnings Season
by Zacks Equity Research
Walgreens Boots Alliance (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Retail Pharmacy USA Aid Walgreen Boots' (WBA) Q2 Earnings?
by Zacks Equity Research
Solid prescription volume growth and brand inflation anticipated to have aided Walgreen Boots' (WBA) Retail Pharmacy USA performance in Q2.
JPMorgan, Wells Fargo, Walgreens, Constellation Brands and Nike are part of Zacks Earnings Preview
by Zacks Equity Research
JPMorgan, Wells Fargo, Walgreens, Constellation Brands and Nike are part of Zacks Earnings Preview
Has the Market Bottomed Already?
by Sheraz Mian
We will discuss below whether the market has bottomed already or not, but this week's record-setting rebound has reemphasized the importance of staying invested to participate in rallies...
Buy Walgreens (WBA) Stock Ahead of its Q2 Fiscal 2020 Earnings Release?
by Benjamin Rains
Should investors think about buying Walgreens stock with the pharmacy and retail giant set to report its Q2 fiscal 2020 earnings results on Thursday, April 2?
Analysts Estimate Walgreens Boots Alliance (WBA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Walgreens (WBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.